EQUITY |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Equity [Abstract] | |
| EQUITY | 13. EQUITY
On October 10, 2024, the Company, Ampersand 2018 Limited Partnership (“Ampersand”) and 1315 Capital II, L.P. (“1315 Capital”, and together with Ampersand, the “Investors”) entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which the Investors exchanged (the “Exchange”) an aggregate of shares of the Company’s Series B Preferred Stock, comprised of shares of Series B Preferred Stock held by Ampersand and shares of Series B Preferred Stock held by 1315 Capital, which represented all of the Company’s issued and outstanding Series B Preferred Stock, for newly created shares of Series C Preferred Stock, at an issuance price per share of $. In the Exchange, Ampersand received shares of Series C Preferred Stock and 1315 Capital received shares of Series C Preferred Stock. The Company recorded approximately $0.2 million in issuance costs related to this transaction.
On January 20, 2026, the Company announced that all shares of Series C Preferred Stock were converted into Common Stock, resulting in the issuance of approximately shares of Common Stock (calculated as $1,000 stated value per preferred share divided by the $2.02 conversion price).
Of this amount, 1315 Capital owns approximately shares of Common Stock, or approximately 34% of Interpace’s outstanding Common Stock, and Ampersand owns shares of Common Stock, or approximately 50% of Interpace’s outstanding Common Stock, in both cases subject to change in connection with subsequent issuance activity and public float changes.
|